Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Shares Issued (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Shares Issued data on record, last reported at -$31.1 million in Q4 2025.

  • For Q4 2025, Shares Issued fell 151.99% year-over-year to -$31.1 million; the TTM value through Sep 2025 reached $18.8 million, up 110.7%, while the annual FY2023 figure was $14.5 million, 31.98% down from the prior year.
  • Shares Issued reached -$31.1 million in Q4 2025 per MIRM's latest filing, down from $16.1 million in the prior quarter.
  • Across five years, Shares Issued topped out at $198.9 million in Q3 2023 and bottomed at -$187.9 million in Q4 2023.
  • Average Shares Issued over 5 years is $3.1 million, with a median of $5.6 million recorded in 2021.
  • The widest YoY moves for Shares Issued: up 880.37% in 2023, down 1274.71% in 2023.
  • A 5-year view of Shares Issued shows it stood at $5.6 million in 2021, then skyrocketed by 188.13% to $16.0 million in 2022, then plummeted by 1274.71% to -$187.9 million in 2023, then skyrocketed by 93.42% to -$12.4 million in 2024, then crashed by 151.99% to -$31.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were -$31.1 million in Q4 2025, $16.1 million in Q3 2025, and $8.7 million in Q2 2025.